<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39310055</PMID><DateRevised><Year>2024</Year><Month>09</Month><Day>24</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">2667-100X</ISSN><JournalIssue CitedMedium="Internet"><Volume>4</Volume><Issue>4</Issue><PubDate><Year>2024</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Journal of intensive medicine</Title><ISOAbbreviation>J Intensive Med</ISOAbbreviation></Journal><ArticleTitle>Glucocorticoid therapy for acute respiratory distress syndrome: Current concepts.</ArticleTitle><Pagination><StartPage>417</StartPage><EndPage>432</EndPage><MedlinePgn>417-432</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jointm.2024.02.002</ELocationID><Abstract><AbstractText>Acute respiratory distress syndrome (ARDS), a fatal critical disease, is induced by various insults. ARDS represents a major global public health burden, and the management of ARDS continues to challenge healthcare systems globally, especially during the pandemic of the coronavirus disease 2019 (COVID-19). There remains no confirmed specific pharmacotherapy for ARDS, despite advances in understanding its pathophysiology. Debate continues about the potential role of glucocorticoids (GCs) as a promising ARDS clinical therapy. Questions regarding GC agent, dose, and duration in patients with ARDS need to be answered, because of substantial variations in GC administration regimens across studies. ARDS heterogeneity likely affects the therapeutic actions of exogenous GCs. This review includes progress in determining the GC mechanisms of action and clinical applications in ARDS, especially during the COVID-19 pandemic.</AbstractText><CopyrightInformation>© 2024 The Authors.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Zhao</LastName><ForeName>Yuanrui</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Critical Care Medicine, Renmin Hospital of Wuhan University, Wuhan, Hubei, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yao</LastName><ForeName>Zhun</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Department of Critical Care Medicine, Renmin Hospital of Wuhan University, Wuhan, Hubei, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>Song</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Critical Care Medicine, Renmin Hospital of Wuhan University, Wuhan, Hubei, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yao</LastName><ForeName>Lan</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Critical Care Medicine, Renmin Hospital of Wuhan University, Wuhan, Hubei, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yu</LastName><ForeName>Zhui</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Department of Critical Care Medicine, Renmin Hospital of Wuhan University, Wuhan, Hubei, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>04</Month><Day>01</Day></ArticleDate></Article><MedlineJournalInfo><Country>China</Country><MedlineTA>J Intensive Med</MedlineTA><NlmUniqueID>9918539389006676</NlmUniqueID><ISSNLinking>2667-100X</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Acute respiratory distress syndrome</Keyword><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Clinical trials</Keyword><Keyword MajorTopicYN="N">Glucocorticoids</Keyword><Keyword MajorTopicYN="N">Heterogeneity</Keyword><Keyword MajorTopicYN="N">Steroids</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>10</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>1</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>2</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>9</Month><Day>23</Day><Hour>7</Hour><Minute>30</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>9</Month><Day>23</Day><Hour>7</Hour><Minute>29</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>9</Month><Day>23</Day><Hour>5</Hour><Minute>57</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>4</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39310055</ArticleId><ArticleId IdType="pmc">PMC11411438</ArticleId><ArticleId IdType="doi">10.1016/j.jointm.2024.02.002</ArticleId><ArticleId IdType="pii">S2667-100X(24)00033-1</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Meyer N.J., Gattinoni L., Calfee C.S. Acute respiratory distress syndrome. Lancet. 2021;398(10300):622–637. doi: 10.1016/s0140-6736(21)00439-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0140-6736(21)00439-6</ArticleId><ArticleId IdType="pmc">PMC8248927</ArticleId><ArticleId IdType="pubmed">34217425</ArticleId></ArticleIdList></Reference><Reference><Citation>Definition A.R.D.S., Ranieri V.M., Rubenfeld G.D., Thompson B.T., Ferguson N.D., Caldwell E., et al. Acute respiratory distress syndrome: the Berlin Definition. JAMA. 2012;307(23):2526–2533. doi: 10.1001/jama.2012.5669.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2012.5669</ArticleId><ArticleId IdType="pubmed">22797452</ArticleId></ArticleIdList></Reference><Reference><Citation>Gorman E.A., O'Kane C.M., McAuley D.F. Acute respiratory distress syndrome in adults: diagnosis, outcomes, long-term sequelae, and management. Lancet. 2022;400(10358):1157–1170. doi: 10.1016/s0140-6736(22)01439-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0140-6736(22)01439-8</ArticleId><ArticleId IdType="pubmed">36070788</ArticleId></ArticleIdList></Reference><Reference><Citation>Matthay M.A., Arabi Y., Arroliga A.C., Bernard G., Bersten A.D., Brochard L.J., et al. A new global definition of acute respiratory distress syndrome. Am J Respir Crit Care Med. 2023;209(1):37–47. doi: 10.1164/rccm.202303-0558WS.</Citation><ArticleIdList><ArticleId IdType="doi">10.1164/rccm.202303-0558WS</ArticleId><ArticleId IdType="pmc">PMC10870872</ArticleId><ArticleId IdType="pubmed">37487152</ArticleId></ArticleIdList></Reference><Reference><Citation>van der Ven F.L.I.M., Valk C.M.A., Blok S., Brouwer M.G., Go D.M., Lokhorst A., et al. Broadening the Berlin definition of ARDS to patients receiving high-flow nasal oxygen: an observational study in patients with acute hypoxemic respiratory failure due to COVID-19. Ann Intensive Care. 2023;13(1):64. doi: 10.1186/s13613-023-01161-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13613-023-01161-6</ArticleId><ArticleId IdType="pmc">PMC10349031</ArticleId><ArticleId IdType="pubmed">37452196</ArticleId></ArticleIdList></Reference><Reference><Citation>Sjoding M.W., Dickson R.P., Iwashyna T.J., Gay S.E., Valley T.S. Racial bias in pulse oximetry measurement. N Engl J Med. 2020;383(25):2477–2478. doi: 10.1056/NEJMc2029240.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMc2029240</ArticleId><ArticleId IdType="pmc">PMC7808260</ArticleId><ArticleId IdType="pubmed">33326721</ArticleId></ArticleIdList></Reference><Reference><Citation>Fawzy A., Wu T.D., Wang K., Robinson M.L., Farha J., Bradke A., et al. Racial and ethnic discrepancy in pulse oximetry and delayed identification of treatment eligibility among patients with COVID-19. JAMA Intern Med. 2022;182(7):730–738. doi: 10.1001/jamainternmed.2022.1906.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamainternmed.2022.1906</ArticleId><ArticleId IdType="pmc">PMC9257583</ArticleId><ArticleId IdType="pubmed">35639368</ArticleId></ArticleIdList></Reference><Reference><Citation>Ranieri V.M., Rubenfeld G., Slutsky A.S. Rethinking acute respiratory distress syndrome after COVID-19: if a "better" definition is the answer, what is the question? Am J Respir Crit Care Med. 2023;207(3):255–260. doi: 10.1164/rccm.202206-1048CP.</Citation><ArticleIdList><ArticleId IdType="doi">10.1164/rccm.202206-1048CP</ArticleId><ArticleId IdType="pmc">PMC9896638</ArticleId><ArticleId IdType="pubmed">36150099</ArticleId></ArticleIdList></Reference><Reference><Citation>Bellani G., Laffey J.G., Pham T., Fan E., Brochard L., Esteban A., et al. Epidemiology, patterns of care, and mortality for patients with acute respiratory distress syndrome in intensive care units in 50 countries. JAMA. 2016;315(8):788–800. doi: 10.1001/jama.2016.0291.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2016.0291</ArticleId><ArticleId IdType="pubmed">26903337</ArticleId></ArticleIdList></Reference><Reference><Citation>Kwizera A., Kabatooro D., Atumanya P., Tumukunde J., Kalungi J., Mwanje A.K., et al. Respiratory support techniques for COVID-19-related ARDS in a Sub-Saharan African country: a multicenter observational study. Chest. 2023;164(2):369–380. doi: 10.1016/j.chest.2023.01.039.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chest.2023.01.039</ArticleId><ArticleId IdType="pmc">PMC9911971</ArticleId><ArticleId IdType="pubmed">36773933</ArticleId></ArticleIdList></Reference><Reference><Citation>Standiford T.J., Ward P.A. Therapeutic targeting of acute lung injury and acute respiratory distress syndrome. Transl Res. 2016;167(1):183–191. doi: 10.1016/j.trsl.2015.04.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.trsl.2015.04.015</ArticleId><ArticleId IdType="pmc">PMC4635065</ArticleId><ArticleId IdType="pubmed">26003524</ArticleId></ArticleIdList></Reference><Reference><Citation>Jonas A.M., Raj R. Vaping-related acute parenchymal lung injury: a systematic review. Chest. 2020;158(4):1555–1565. doi: 10.1016/j.chest.2020.03.085.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chest.2020.03.085</ArticleId><ArticleId IdType="pubmed">32442559</ArticleId></ArticleIdList></Reference><Reference><Citation>Attaway A.H., Scheraga R.G., Bhimraj A., Biehl M., Hatipoğlu U. Severe COVID-19 pneumonia: pathogenesis and clinical management. BMJ. 2021;372:n436. doi: 10.1136/bmj.n436.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.n436</ArticleId><ArticleId IdType="pubmed">33692022</ArticleId></ArticleIdList></Reference><Reference><Citation>Thompson B.T., Chambers R.C., Liu K.D. Acute respiratory distress syndrome. N Engl J Med. 2017;377(6):562–572. doi: 10.1056/NEJMra1608077.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMra1608077</ArticleId><ArticleId IdType="pubmed">28792873</ArticleId></ArticleIdList></Reference><Reference><Citation>Laffey J.G., Madotto F., Bellani G., Pham T., Fan E., Brochard L., et al. Geo-economic variations in epidemiology, patterns of care, and outcomes in patients with acute respiratory distress syndrome: insights from the LUNG SAFE prospective cohort study. Lancet Respir Med. 2017;5(8):627–638. doi: 10.1016/s2213-2600(17)30213-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s2213-2600(17)30213-8</ArticleId><ArticleId IdType="pubmed">28624388</ArticleId></ArticleIdList></Reference><Reference><Citation>Matthay M.A., Zemans R.L., Zimmerman G.A., Arabi Y.M., Beitler J.R., Mercat A., et al. Acute respiratory distress syndrome. Nat Rev Dis Primers. 2019;5(1):18. doi: 10.1038/s41572-019-0069-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41572-019-0069-0</ArticleId><ArticleId IdType="pmc">PMC6709677</ArticleId><ArticleId IdType="pubmed">30872586</ArticleId></ArticleIdList></Reference><Reference><Citation>Group I.C.C.T. Acute lung injury and the acute respiratory distress syndrome in Ireland: a prospective audit of epidemiology and management. Crit Care. 2008;12(1):R30. doi: 10.1186/cc6808.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/cc6808</ArticleId><ArticleId IdType="pmc">PMC2374618</ArticleId><ArticleId IdType="pubmed">18312626</ArticleId></ArticleIdList></Reference><Reference><Citation>Bos L.D.J., Ware L.B. Acute respiratory distress syndrome: causes, pathophysiology, and phenotypes. Lancet. 2022;400(10358):1145–1156. doi: 10.1016/s0140-6736(22)01485-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0140-6736(22)01485-4</ArticleId><ArticleId IdType="pubmed">36070787</ArticleId></ArticleIdList></Reference><Reference><Citation>Matthay M.A., Ware L.B., Zimmerman G.A. The acute respiratory distress syndrome. J Clin Invest. 2012;122(8):2731–2740. doi: 10.1172/jci60331.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/jci60331</ArticleId><ArticleId IdType="pmc">PMC3408735</ArticleId><ArticleId IdType="pubmed">22850883</ArticleId></ArticleIdList></Reference><Reference><Citation>Williams A.E., Chambers R.C. The mercurial nature of neutrophils: still an enigma in ARDS? Am J Physiol Lung Cell Mol Physiol. 2014;306(3):L217–L230. doi: 10.1152/ajplung.00311.2013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/ajplung.00311.2013</ArticleId><ArticleId IdType="pmc">PMC3920201</ArticleId><ArticleId IdType="pubmed">24318116</ArticleId></ArticleIdList></Reference><Reference><Citation>Zemans R.L., Matthay M.A. What drives neutrophils to the alveoli in ARDS? Thorax. 2017;72(1):1–3. doi: 10.1136/thoraxjnl-2016-209170.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/thoraxjnl-2016-209170</ArticleId><ArticleId IdType="pmc">PMC5889088</ArticleId><ArticleId IdType="pubmed">27974631</ArticleId></ArticleIdList></Reference><Reference><Citation>Ballabh P., Kumari J., Krauss A.N., Shin J.J., Jain A., Auld P.A., et al. Soluble E-selectin, soluble l-selectin and soluble ICAM-1 in bronchopulmonary dysplasia, and changes with dexamethasone. Pediatrics. 2003;111(3):461–468. doi: 10.1542/peds.111.3.461.</Citation><ArticleIdList><ArticleId IdType="doi">10.1542/peds.111.3.461</ArticleId><ArticleId IdType="pubmed">12612222</ArticleId></ArticleIdList></Reference><Reference><Citation>Dagenais A., Fréchette R., Yamagata Y., Yamagata T., Carmel J.F., Clermont M.E., et al. Downregulation of ENaC activity and expression by TNF-alpha in alveolar epithelial cells. Am J Physiol Lung Cell Mol Physiol. 2004;286(2):L301–L311. doi: 10.1152/ajplung.00326.2002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/ajplung.00326.2002</ArticleId><ArticleId IdType="pubmed">14514522</ArticleId></ArticleIdList></Reference><Reference><Citation>Eaton D.C., Helms M.N., Koval M., Bao H.F., Jain L. The contribution of epithelial sodium channels to alveolar function in health and disease. Annu Rev Physiol. 2009;71:403–423. doi: 10.1146/annurev.physiol.010908.163250.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev.physiol.010908.163250</ArticleId><ArticleId IdType="pubmed">18831683</ArticleId></ArticleIdList></Reference><Reference><Citation>Short K.R., Kasper J., van der Aa S., Andeweg A.C., Zaaraoui-Boutahar F., Goeijenbier M., et al. Influenza virus damages the alveolar barrier by disrupting epithelial cell tight junctions. Eur Respir J. 2016;47(3):954–966. doi: 10.1183/13993003.01282-2015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1183/13993003.01282-2015</ArticleId><ArticleId IdType="pubmed">26743480</ArticleId></ArticleIdList></Reference><Reference><Citation>McCubbrey A.L., Curtis J.L. Efferocytosis and lung disease. Chest. 2013;143(6):1750–1757. doi: 10.1378/chest.12-2413.</Citation><ArticleIdList><ArticleId IdType="doi">10.1378/chest.12-2413</ArticleId><ArticleId IdType="pmc">PMC3673667</ArticleId><ArticleId IdType="pubmed">23732585</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen X., Tang J., Shuai W., Meng J., Feng J., Han Z. Macrophage polarization and its role in the pathogenesis of acute lung injury/acute respiratory distress syndrome. Inflamm Res. 2020;69(9):883–895. doi: 10.1007/s00011-020-01378-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00011-020-01378-2</ArticleId><ArticleId IdType="pmc">PMC7347666</ArticleId><ArticleId IdType="pubmed">32647933</ArticleId></ArticleIdList></Reference><Reference><Citation>Short K.R., Kroeze E.J.B.V., Fouchier R.A.M., Kuiken T. Pathogenesis of influenza-induced acute respiratory distress syndrome. Lancet Infect Dis. 2014;14(1):57–69. doi: 10.1016/s1473-3099(13)70286-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s1473-3099(13)70286-x</ArticleId><ArticleId IdType="pubmed">24239327</ArticleId></ArticleIdList></Reference><Reference><Citation>Matthay M.A. Resolution of pulmonary edema. Thirty years of progress. Am J Respir Crit Care Med. 2014;189(11):1301–1308. doi: 10.1164/rccm.201403-0535OE.</Citation><ArticleIdList><ArticleId IdType="doi">10.1164/rccm.201403-0535OE</ArticleId><ArticleId IdType="pmc">PMC4098087</ArticleId><ArticleId IdType="pubmed">24881936</ArticleId></ArticleIdList></Reference><Reference><Citation>Grégoire M., Uhel F., Lesouhaitier M., Gacouin A., Guirriec M., Mourcin F., et al. Impaired efferocytosis and neutrophil extracellular trap clearance by macrophages in ARDS. Eur Respir J. 2018;52(2) doi: 10.1183/13993003.02590-2017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1183/13993003.02590-2017</ArticleId><ArticleId IdType="pubmed">29946009</ArticleId></ArticleIdList></Reference><Reference><Citation>Scott B.N.V., Kubes P. Death to the neutrophil! A resolution for acute respiratory distress syndrome? Eur Respir J. 2018;52(2) doi: 10.1183/13993003.01274-2018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1183/13993003.01274-2018</ArticleId><ArticleId IdType="pubmed">30072544</ArticleId></ArticleIdList></Reference><Reference><Citation>Diwanji N., Bergmann A. Basement membrane damage by ROS- and JNK-mediated Mmp2 activation drives macrophage recruitment to overgrown tissue. Nat Commun. 2020;11(1):3631. doi: 10.1038/s41467-020-17399-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-020-17399-8</ArticleId><ArticleId IdType="pmc">PMC7371875</ArticleId><ArticleId IdType="pubmed">32686670</ArticleId></ArticleIdList></Reference><Reference><Citation>Qadir N., SY Chang. Pharmacologic treatments for acute respiratory distress syndrome. Crit Care Clin. 2021;37(4):877–893. doi: 10.1016/j.ccc.2021.05.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ccc.2021.05.009</ArticleId><ArticleId IdType="pmc">PMC8449143</ArticleId><ArticleId IdType="pubmed">34548139</ArticleId></ArticleIdList></Reference><Reference><Citation>Kadmiel M., Cidlowski J.A. Glucocorticoid receptor signaling in health and disease. Trends Pharmacol Sci. 2013;34(9):518–530. doi: 10.1016/j.tips.2013.07.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tips.2013.07.003</ArticleId><ArticleId IdType="pmc">PMC3951203</ArticleId><ArticleId IdType="pubmed">23953592</ArticleId></ArticleIdList></Reference><Reference><Citation>Berrebi D., Bruscoli S., Cohen N., Foussat A., Migliorati G., Bouchet-Delbos L., et al. Synthesis of glucocorticoid-induced leucine zipper (GILZ) by macrophages: an anti-inflammatory and immunosuppressive mechanism shared by glucocorticoids and IL-10. Blood. 2003;101(2):729–738. doi: 10.1182/blood-2002-02-0538.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2002-02-0538</ArticleId><ArticleId IdType="pubmed">12393603</ArticleId></ArticleIdList></Reference><Reference><Citation>Ayroldi E., Riccardi C. Glucocorticoid-induced leucine zipper (GILZ): a new important mediator of glucocorticoid action. FASEB J. 2009;23(11):3649–3658. doi: 10.1096/fj.09-134684.</Citation><ArticleIdList><ArticleId IdType="doi">10.1096/fj.09-134684</ArticleId><ArticleId IdType="pubmed">19567371</ArticleId></ArticleIdList></Reference><Reference><Citation>Abraham S.M., Lawrence T., Kleiman A., Warden P., Medghalchi M., Tuckermann J., et al. Antiinflammatory effects of dexamethasone are partly dependent on induction of dual specificity phosphatase 1. J Exp Med. 2006;203(8):1883–1889. doi: 10.1084/jem.20060336.</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20060336</ArticleId><ArticleId IdType="pmc">PMC2118371</ArticleId><ArticleId IdType="pubmed">16880258</ArticleId></ArticleIdList></Reference><Reference><Citation>Hammer M., Mages J., Dietrich H., Servatius A., Howells N., Cato A.C., et al. Dual specificity phosphatase 1 (DUSP1) regulates a subset of LPS-induced genes and protects mice from lethal endotoxin shock. J Exp Med. 2006;203(1):15–20. doi: 10.1084/jem.20051753.</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20051753</ArticleId><ArticleId IdType="pmc">PMC2118077</ArticleId><ArticleId IdType="pubmed">16380512</ArticleId></ArticleIdList></Reference><Reference><Citation>Minghetti L., Nicolini A., Polazzi E., Greco A., Perretti M., Parente L., et al. Down-regulation of microglial cyclo-oxygenase-2 and inducible nitric oxide synthase expression by lipocortin 1. Br J Pharmacol. 1999;126(6):1307–1314. doi: 10.1038/sj.bjp.0702423.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sj.bjp.0702423</ArticleId><ArticleId IdType="pmc">PMC1565901</ArticleId><ArticleId IdType="pubmed">10217523</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu C.C., Croxtall J.D., Perretti M., Bryant C.E., Thiemermann C., Flower R.J., et al. Lipocortin 1 mediates the inhibition by dexamethasone of the induction by endotoxin of nitric oxide synthase in the rat. Proc Natl Acad Sci U S A. 1995;92(8):3473–3477. doi: 10.1073/pnas.92.8.3473.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.92.8.3473</ArticleId><ArticleId IdType="pmc">PMC42189</ArticleId><ArticleId IdType="pubmed">7536934</ArticleId></ArticleIdList></Reference><Reference><Citation>Perretti M., Croxtall J.D., Wheller S.K., Goulding N.J., Hannon R., Flower R.J. Mobilizing lipocortin 1 in adherent human leukocytes downregulates their transmigration. Nat Med. 1996;2(11):1259–1262. doi: 10.1038/nm1196-1259.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm1196-1259</ArticleId><ArticleId IdType="pubmed">8898757</ArticleId></ArticleIdList></Reference><Reference><Citation>Lim H.Y., Müller N., Herold M.J., van den Brandt J., Reichardt H.M. Glucocorticoids exert opposing effects on macrophage function dependent on their concentration. Immunology. 2007;122(1):47–53. doi: 10.1111/j.1365-2567.2007.02611.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2567.2007.02611.x</ArticleId><ArticleId IdType="pmc">PMC2265978</ArticleId><ArticleId IdType="pubmed">17451463</ArticleId></ArticleIdList></Reference><Reference><Citation>Saraiva M., O'Garra A. The regulation of IL-10 production by immune cells. Nat Rev Immunol. 2010;10(3):170–181. doi: 10.1038/nri2711.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nri2711</ArticleId><ArticleId IdType="pubmed">20154735</ArticleId></ArticleIdList></Reference><Reference><Citation>Vettorazzi S., Bode C., Dejager L., Frappart L., Shelest E., Klaßen C., et al. Glucocorticoids limit acute lung inflammation in concert with inflammatory stimuli by induction of SphK1. Nat Commun. 2015;6:7796. doi: 10.1038/ncomms8796.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncomms8796</ArticleId><ArticleId IdType="pmc">PMC4518295</ArticleId><ArticleId IdType="pubmed">26183376</ArticleId></ArticleIdList></Reference><Reference><Citation>Ehrchen J.M., Roth J., Barczyk-Kahlert K. More than suppression: glucocorticoid action on monocytes and macrophages. Front Immunol. 2019;10:2028. doi: 10.3389/fimmu.2019.02028.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2019.02028</ArticleId><ArticleId IdType="pmc">PMC6718555</ArticleId><ArticleId IdType="pubmed">31507614</ArticleId></ArticleIdList></Reference><Reference><Citation>Perretti M., Ahluwalia A. The microcirculation and inflammation: site of action for glucocorticoids. Microcirculation. 2000;7(3):147–161. doi: 10.1111/j.1549-8719.2000.tb00117.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1549-8719.2000.tb00117.x</ArticleId><ArticleId IdType="pubmed">10901495</ArticleId></ArticleIdList></Reference><Reference><Citation>Baschant U., Tuckermann J. The role of the glucocorticoid receptor in inflammation and immunity. J Steroid Biochem Mol Biol. 2010;120(2–3):69–75. doi: 10.1016/j.jsbmb.2010.03.058.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jsbmb.2010.03.058</ArticleId><ArticleId IdType="pubmed">20346397</ArticleId></ArticleIdList></Reference><Reference><Citation>Morgan D.J., Davis D.M. Distinct effects of dexamethasone on human natural killer cell responses dependent on cytokines. Front Immunol. 2017;8:432. doi: 10.3389/fimmu.2017.00432.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2017.00432</ArticleId><ArticleId IdType="pmc">PMC5389971</ArticleId><ArticleId IdType="pubmed">28450865</ArticleId></ArticleIdList></Reference><Reference><Citation>Franco L.M., Gadkari M., Howe K.N., Sun J., Kardava L., Kumar P., et al. Immune regulation by glucocorticoids can be linked to cell type-dependent transcriptional responses. J Exp Med. 2019;216(2):384–406. doi: 10.1084/jem.20180595.</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20180595</ArticleId><ArticleId IdType="pmc">PMC6363437</ArticleId><ArticleId IdType="pubmed">30674564</ArticleId></ArticleIdList></Reference><Reference><Citation>Taves M.D., Ashwell J.D. Glucocorticoids in T cell development, differentiation and function. Nat Rev Immunol. 2021;21(4):233–243. doi: 10.1038/s41577-020-00464-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41577-020-00464-0</ArticleId><ArticleId IdType="pubmed">33149283</ArticleId></ArticleIdList></Reference><Reference><Citation>Liberman A.C., Druker J., Perone M.J., Arzt E. Glucocorticoids in the regulation of transcription factors that control cytokine synthesis. Cytokine Growth Factor Rev. 2007;18(1–2):45–56. doi: 10.1016/j.cytogfr.2007.01.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cytogfr.2007.01.005</ArticleId><ArticleId IdType="pubmed">17336577</ArticleId></ArticleIdList></Reference><Reference><Citation>Li C.C., Munitic I., Mittelstadt P.R., Castro E., Ashwell J.D. Suppression of dendritic cell-derived IL-12 by endogenous glucocorticoids is protective in LPS-induced sepsis. PLoS Biol. 2015;13(10) doi: 10.1371/journal.pbio.1002269.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pbio.1002269</ArticleId><ArticleId IdType="pmc">PMC4595142</ArticleId><ArticleId IdType="pubmed">26440998</ArticleId></ArticleIdList></Reference><Reference><Citation>Oh K.S., Patel H., Gottschalk R.A., Lee W.S., Baek S., Fraser I.D.C., et al. Anti-inflammatory chromatinscape suggests alternative mechanisms of glucocorticoid receptor action. Immunity. 2017;47(2) doi: 10.1016/j.immuni.2017.07.012. 298.e–309.e.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2017.07.012</ArticleId><ArticleId IdType="pmc">PMC5572836</ArticleId><ArticleId IdType="pubmed">28801231</ArticleId></ArticleIdList></Reference><Reference><Citation>Banuelos J., Shin S., Cao Y., Bochner B.S., Morales-Nebreda L., Budinger G.R., et al. BCL-2 protects human and mouse Th17 cells from glucocorticoid-induced apoptosis. Allergy. 2016;71(5):640–650. doi: 10.1111/all.12840.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/all.12840</ArticleId><ArticleId IdType="pmc">PMC4844778</ArticleId><ArticleId IdType="pubmed">26752231</ArticleId></ArticleIdList></Reference><Reference><Citation>de Castro Kroner J., Knoke K., Kofler D.M., Steiger J., Fabri M. Glucocorticoids promote intrinsic human T(H)17 differentiation. J Allergy Clin Immunol. 2018;142(5) doi: 10.1016/j.jaci.2018.07.019. 1669.e–73.e.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaci.2018.07.019</ArticleId><ArticleId IdType="pubmed">30092286</ArticleId></ArticleIdList></Reference><Reference><Citation>Busillo J.M., Cidlowski J.A. The five Rs of glucocorticoid action during inflammation: ready, reinforce, repress, resolve, and restore. Trends Endocrinol Metab. 2013;24(3):109–119. doi: 10.1016/j.tem.2012.11.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tem.2012.11.005</ArticleId><ArticleId IdType="pmc">PMC3667973</ArticleId><ArticleId IdType="pubmed">23312823</ArticleId></ArticleIdList></Reference><Reference><Citation>Busillo J.M., Azzam K.M., Cidlowski J.A. Glucocorticoids sensitize the innate immune system through regulation of the NLRP3 inflammasome. J Biol Chem. 2011;286(44):38703–38713. doi: 10.1074/jbc.M111.275370.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M111.275370</ArticleId><ArticleId IdType="pmc">PMC3207479</ArticleId><ArticleId IdType="pubmed">21940629</ArticleId></ArticleIdList></Reference><Reference><Citation>Filep J.G., Delalandre A., Payette Y., Földes-Filep E. Glucocorticoid receptor regulates expression of l-selectin and CD11/CD18 on human neutrophils. Circulation. 1997;96(1):295–301. doi: 10.1161/01.cir.96.1.295.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/01.cir.96.1.295</ArticleId><ArticleId IdType="pubmed">9236448</ArticleId></ArticleIdList></Reference><Reference><Citation>Cronstein B.N., Kimmel S.C., Levin R.I., Martiniuk F., Weissmann G. A mechanism for the antiinflammatory effects of corticosteroids: the glucocorticoid receptor regulates leukocyte adhesion to endothelial cells and expression of endothelial-leukocyte adhesion molecule 1 and intercellular adhesion molecule 1. Proc Natl Acad Sci U S A. 1992;89(21):9991–9995. doi: 10.1073/pnas.89.21.9991.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.89.21.9991</ArticleId><ArticleId IdType="pmc">PMC50263</ArticleId><ArticleId IdType="pubmed">1279685</ArticleId></ArticleIdList></Reference><Reference><Citation>Tuckermann J.P., Kleiman A., McPherson K.G., Reichardt H.M. Molecular mechanisms of glucocorticoids in the control of inflammation and lymphocyte apoptosis. Crit Rev Clin Lab Sci. 2005;42(1):71–104. doi: 10.1080/10408360590888983.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/10408360590888983</ArticleId><ArticleId IdType="pubmed">15697171</ArticleId></ArticleIdList></Reference><Reference><Citation>Masferrer J.L., Seibert K., Zweifel B., Needleman P. Endogenous glucocorticoids regulate an inducible cyclooxygenase enzyme. Proc Natl Acad Sci U S A. 1992;89(9):3917–3921. doi: 10.1073/pnas.89.9.3917.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.89.9.3917</ArticleId><ArticleId IdType="pmc">PMC525602</ArticleId><ArticleId IdType="pubmed">1570314</ArticleId></ArticleIdList></Reference><Reference><Citation>Amratia D.A., Viola H., Ioachimescu O.C. Glucocorticoid therapy in respiratory illness: bench to bedside. J Investig Med. 2022;70(8):1662–1680. doi: 10.1136/jim-2021-002161.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jim-2021-002161</ArticleId><ArticleId IdType="pmc">PMC9726965</ArticleId><ArticleId IdType="pubmed">35764344</ArticleId></ArticleIdList></Reference><Reference><Citation>Sugimoto M.A., Vago J.P., Teixeira M.M., Sousa L.P. Annexin A1 and the resolution of inflammation: modulation of neutrophil recruitment, apoptosis, and clearance. J Immunol Res. 2016;2016 doi: 10.1155/2016/8239258.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2016/8239258</ArticleId><ArticleId IdType="pmc">PMC4738713</ArticleId><ArticleId IdType="pubmed">26885535</ArticleId></ArticleIdList></Reference><Reference><Citation>Miyata M., Lee J.Y., Susuki-Miyata S., Wang W.Y., Xu H., Kai H., et al. Glucocorticoids suppress inflammation via the upregulation of negative regulator IRAK-M. Nat Commun. 2015;6:6062. doi: 10.1038/ncomms7062.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncomms7062</ArticleId><ArticleId IdType="pmc">PMC4309435</ArticleId><ArticleId IdType="pubmed">25585690</ArticleId></ArticleIdList></Reference><Reference><Citation>Marik P.E., Meduri G.U., Rocco P.R., Annane D. Glucocorticoid treatment in acute lung injury and acute respiratory distress syndrome. Crit Care Clin. 2011;27(3):589–607. doi: 10.1016/j.ccc.2011.05.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ccc.2011.05.007</ArticleId><ArticleId IdType="pubmed">21742218</ArticleId></ArticleIdList></Reference><Reference><Citation>Ehrchen J., Steinmüller L., Barczyk K., Tenbrock K., Nacken W., Eisenacher M., et al. Glucocorticoids induce differentiation of a specifically activated, anti-inflammatory subtype of human monocytes. Blood. 2007;109(3):1265–1274. doi: 10.1182/blood-2006-02-001115.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2006-02-001115</ArticleId><ArticleId IdType="pubmed">17018861</ArticleId></ArticleIdList></Reference><Reference><Citation>Yin S., Ding M., Fan L., Yu X., Liang Z., Wu L., et al. Inhibition of inflammation and regulation of AQPs/ENaCs/Na(+)-K(+)-ATPase mediated alveolar fluid transport by total flavonoids extracted from Nervilia fordii in lipopolysaccharide-induced acute lung injury. Front Pharmacol. 2021;12 doi: 10.3389/fphar.2021.603863.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphar.2021.603863</ArticleId><ArticleId IdType="pmc">PMC8650715</ArticleId><ArticleId IdType="pubmed">34887746</ArticleId></ArticleIdList></Reference><Reference><Citation>Panettieri R.A., Schaafsma D., Amrani Y., Koziol-White C., Ostrom R., Tliba O. Non-genomic effects of glucocorticoids: an updated view. Trends Pharmacol Sci. 2019;40(1):38–49. doi: 10.1016/j.tips.2018.11.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tips.2018.11.002</ArticleId><ArticleId IdType="pmc">PMC7106476</ArticleId><ArticleId IdType="pubmed">30497693</ArticleId></ArticleIdList></Reference><Reference><Citation>Meduri G.U. The role of the host defence response in the progression and outcome of ARDS: pathophysiological correlations and response to glucocorticoid treatment. Eur Respir J. 1996;9(12):2650–2670. doi: 10.1183/09031936.96.09122650.</Citation><ArticleIdList><ArticleId IdType="doi">10.1183/09031936.96.09122650</ArticleId><ArticleId IdType="pubmed">8980983</ArticleId></ArticleIdList></Reference><Reference><Citation>Meduri G.U., Tolley E.A., Chinn A., Stentz F., Postlethwaite A. Procollagen types I and III aminoterminal propeptide levels during acute respiratory distress syndrome and in response to methylprednisolone treatment. Am J Respir Crit Care Med. 1998;158(5 Pt 1):1432–1441. doi: 10.1164/ajrccm.158.5.9801107.</Citation><ArticleIdList><ArticleId IdType="doi">10.1164/ajrccm.158.5.9801107</ArticleId><ArticleId IdType="pubmed">9817690</ArticleId></ArticleIdList></Reference><Reference><Citation>van Zaane B., Nur E., Squizzato A., Gerdes V.E., Büller H.R., Dekkers O.M., et al. Systematic review on the effect of glucocorticoid use on procoagulant, anti-coagulant and fibrinolytic factors. J Thromb Haemost. 2010;8(11):2483–2493. doi: 10.1111/j.1538-7836.2010.04034.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1538-7836.2010.04034.x</ArticleId><ArticleId IdType="pubmed">20735729</ArticleId></ArticleIdList></Reference><Reference><Citation>Ayroldi E., Zollo O., Bastianelli A., Marchetti C., Agostini M., Di Virgilio R., et al. GILZ mediates the antiproliferative activity of glucocorticoids by negative regulation of Ras signaling. J Clin Invest. 2007;117(6):1605–1615. doi: 10.1172/jci30724.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/jci30724</ArticleId><ArticleId IdType="pmc">PMC1865030</ArticleId><ArticleId IdType="pubmed">17492054</ArticleId></ArticleIdList></Reference><Reference><Citation>Beitler J.R., Thompson B.T., Baron R.M., Bastarache J.A., Denlinger L.C., Esserman L., et al. Advancing precision medicine for acute respiratory distress syndrome. Lancet Respir Med. 2022;10(1):107–120. doi: 10.1016/s2213-2600(21)00157-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s2213-2600(21)00157-0</ArticleId><ArticleId IdType="pmc">PMC8302189</ArticleId><ArticleId IdType="pubmed">34310901</ArticleId></ArticleIdList></Reference><Reference><Citation>Wick K.D., Aggarwal N.R., Curley M.A.Q., Fowler A.A., 3rd, Jaber S., Kostrubiec M., et al. Opportunities for improved clinical trial designs in acute respiratory distress syndrome. Lancet Respir Med. 2022;10(9):916–924. doi: 10.1016/s2213-2600(22)00294-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s2213-2600(22)00294-6</ArticleId><ArticleId IdType="pubmed">36057279</ArticleId></ArticleIdList></Reference><Reference><Citation>Prescott H.C., Calfee C.S., Thompson B.T., Angus D.C., Liu V.X. Toward smarter lumping and smarter splitting: rethinking strategies for sepsis and acute respiratory distress syndrome clinical trial design. Am J Respir Crit Care Med. 2016;194(2):147–155. doi: 10.1164/rccm.201512-2544CP.</Citation><ArticleIdList><ArticleId IdType="doi">10.1164/rccm.201512-2544CP</ArticleId><ArticleId IdType="pmc">PMC5003218</ArticleId><ArticleId IdType="pubmed">27244481</ArticleId></ArticleIdList></Reference><Reference><Citation>Ware L.B., Matthay M.A., Mebazaa A. Designing an ARDS trial for 2020 and beyond: focus on enrichment strategies. Intensive Care Med. 2020;46(12):2153–2156. doi: 10.1007/s00134-020-06232-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00134-020-06232-x</ArticleId><ArticleId IdType="pmc">PMC7605340</ArticleId><ArticleId IdType="pubmed">33136196</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferguson N.D., Fan E., Camporota L., Antonelli M., Anzueto A., Beale R., et al. The Berlin definition of ARDS: an expanded rationale, justification, and supplementary material. Intensive Care Med. 2012;38(10):1573–1582. doi: 10.1007/s00134-012-2682-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00134-012-2682-1</ArticleId><ArticleId IdType="pubmed">22926653</ArticleId></ArticleIdList></Reference><Reference><Citation>Beitler J.R., Sarge T., Banner-Goodspeed V.M., Gong M.N., Cook D., Novack V., et al. Effect of titrating positive end-expiratory pressure (PEEP) with an esophageal pressure-guided strategy vs an empirical high PEEP-FiO2 strategy on death and days free from mechanical ventilation among patients with acute respiratory distress syndrome: a randomized clinical trial. JAMA. 2019;321(9):846–857. doi: 10.1001/jama.2019.0555.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2019.0555</ArticleId><ArticleId IdType="pmc">PMC6439595</ArticleId><ArticleId IdType="pubmed">30776290</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilson J.G., Calfee C.S. ARDS subphenotypes: understanding a heterogeneous syndrome. Crit Care. 2020;24(1):102. doi: 10.1186/s13054-020-2778-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13054-020-2778-x</ArticleId><ArticleId IdType="pmc">PMC7092435</ArticleId><ArticleId IdType="pubmed">32204722</ArticleId></ArticleIdList></Reference><Reference><Citation>Wendel Garcia P.D., Caccioppola A., Coppola S., Pozzi T., Ciabattoni A., Cenci S., et al. Latent class analysis to predict intensive care outcomes in acute respiratory distress syndrome: a proposal of two pulmonary phenotypes. Crit Care. 2021;25(1):154. doi: 10.1186/s13054-021-03578-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13054-021-03578-6</ArticleId><ArticleId IdType="pmc">PMC8060783</ArticleId><ArticleId IdType="pubmed">33888134</ArticleId></ArticleIdList></Reference><Reference><Citation>Amato M.B., Meade M.O., Slutsky A.S., Brochard L., Costa E.L., Schoenfeld D.A., et al. Driving pressure and survival in the acute respiratory distress syndrome. N Engl J Med. 2015;372(8):747–755. doi: 10.1056/NEJMsa1410639.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMsa1410639</ArticleId><ArticleId IdType="pubmed">25693014</ArticleId></ArticleIdList></Reference><Reference><Citation>Beitler J.R., Majumdar R., Hubmayr R.D., Malhotra A., Thompson B.T., Owens R.L., et al. Volume delivered during recruitment maneuver predicts lung stress in acute respiratory distress syndrome. Crit Care Med. 2016;44(1):91–99. doi: 10.1097/ccm.0000000000001355.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/ccm.0000000000001355</ArticleId><ArticleId IdType="pmc">PMC5224862</ArticleId><ArticleId IdType="pubmed">26474111</ArticleId></ArticleIdList></Reference><Reference><Citation>Tonelli R., Grasso S., Cortegiani A., Ball L., Castaniere I., Tabbì L., et al. Physiological effects of lung-protective ventilation in patients with lung fibrosis and usual interstitial pneumonia pattern versus primary ARDS: a matched-control study. Crit Care. 2023;27(1):398. doi: 10.1186/s13054-023-04682-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13054-023-04682-5</ArticleId><ArticleId IdType="pmc">PMC10585808</ArticleId><ArticleId IdType="pubmed">37853480</ArticleId></ArticleIdList></Reference><Reference><Citation>Matthay M.A., Arabi Y.M., Siegel E.R., Ware L.B., Bos L.D.J., Sinha P., et al. Phenotypes and personalized medicine in the acute respiratory distress syndrome. Intensive Care Med. 2020;46(12):2136–2152. doi: 10.1007/s00134-020-06296-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00134-020-06296-9</ArticleId><ArticleId IdType="pmc">PMC7673253</ArticleId><ArticleId IdType="pubmed">33206201</ArticleId></ArticleIdList></Reference><Reference><Citation>Constantin J.M., Grasso S., Chanques G., Aufort S., Futier E., Sebbane M., et al. Lung morphology predicts response to recruitment maneuver in patients with acute respiratory distress syndrome. Crit Care Med. 2010;38(4):1108–1117. doi: 10.1097/CCM.0b013e3181d451ec.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/CCM.0b013e3181d451ec</ArticleId><ArticleId IdType="pubmed">20154600</ArticleId></ArticleIdList></Reference><Reference><Citation>Constantin J.M., Jabaudon M., Lefrant J.Y., Jaber S., Quenot J.P., Langeron O., et al. Personalised mechanical ventilation tailored to lung morphology versus low positive end-expiratory pressure for patients with acute respiratory distress syndrome in France (the LIVE study): a multicentre, single-blind, randomised controlled trial. Lancet Respir Med. 2019;7(10):870–880. doi: 10.1016/s2213-2600(19)30138-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s2213-2600(19)30138-9</ArticleId><ArticleId IdType="pubmed">31399381</ArticleId></ArticleIdList></Reference><Reference><Citation>Warren M.A., Zhao Z., Koyama T., Bastarache J.A., Shaver C.M., Semler M.W., et al. Severity scoring of lung oedema on the chest radiograph is associated with clinical outcomes in ARDS. Thorax. 2018;73(9):840–846. doi: 10.1136/thoraxjnl-2017-211280.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/thoraxjnl-2017-211280</ArticleId><ArticleId IdType="pmc">PMC6410734</ArticleId><ArticleId IdType="pubmed">29903755</ArticleId></ArticleIdList></Reference><Reference><Citation>Jabaudon M., Audard J., Pereira B., Jaber S., Lefrant J.Y., Blondonnet R., et al. Early changes over time in the radiographic assessment of lung edema score are associated with survival in ARDS. Chest. 2020;158(6):2394–2403. doi: 10.1016/j.chest.2020.06.070.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chest.2020.06.070</ArticleId><ArticleId IdType="pmc">PMC7768934</ArticleId><ArticleId IdType="pubmed">32659235</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosenberger C.M., Wick K.D., Zhuo H., Wu N., Chen Y., Kapadia S.B., et al. Early plasma angiopoietin-2 is prognostic for ARDS and mortality among critically ill patients with sepsis. Crit Care. 2023;27(1):234. doi: 10.1186/s13054-023-04525-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13054-023-04525-3</ArticleId><ArticleId IdType="pmc">PMC10261831</ArticleId><ArticleId IdType="pubmed">37312169</ArticleId></ArticleIdList></Reference><Reference><Citation>Redaelli S., von Wedel D., Fosset M., Suleiman A., Chen G., Alingrin J., et al. Inflammatory subphenotypes in patients at risk of ARDS: evidence from the LIPS-A trial. Intensive Care Med. 2023;49(12):1499–1507. doi: 10.1007/s00134-023-07244-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00134-023-07244-z</ArticleId><ArticleId IdType="pubmed">37906258</ArticleId></ArticleIdList></Reference><Reference><Citation>Calfee C.S., Delucchi K., Parsons P.E., Thompson B.T., Ware L.B., Matthay M.A., et al. Subphenotypes in acute respiratory distress syndrome: latent class analysis of data from two randomised controlled trials. Lancet Respir Med. 2014;2(8):611–620. doi: 10.1016/s2213-2600(14)70097-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s2213-2600(14)70097-9</ArticleId><ArticleId IdType="pmc">PMC4154544</ArticleId><ArticleId IdType="pubmed">24853585</ArticleId></ArticleIdList></Reference><Reference><Citation>Bos L.D.J., Scicluna B.P., Ong D.S.Y., Cremer O., van der Poll T., Schultz M.J. Understanding heterogeneity in biologic phenotypes of acute respiratory distress syndrome by leukocyte expression profiles. Am J Respir Crit Care Med. 2019;200(1):42–50. doi: 10.1164/rccm.201809-1808OC.</Citation><ArticleIdList><ArticleId IdType="doi">10.1164/rccm.201809-1808OC</ArticleId><ArticleId IdType="pubmed">30645145</ArticleId></ArticleIdList></Reference><Reference><Citation>Bos L.D., Schouten L.R., van Vught L.A., Wiewel M.A., Ong D.S.Y., Cremer O., et al. Identification and validation of distinct biological phenotypes in patients with acute respiratory distress syndrome by cluster analysis. Thorax. 2017;72(10):876–883. doi: 10.1136/thoraxjnl-2016-209719.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/thoraxjnl-2016-209719</ArticleId><ArticleId IdType="pmc">PMC5964254</ArticleId><ArticleId IdType="pubmed">28450529</ArticleId></ArticleIdList></Reference><Reference><Citation>Sinha P., Delucchi K.L., McAuley D.F., O'Kane C.M., Matthay M.A., Calfee C.S. Development and validation of parsimonious algorithms to classify acute respiratory distress syndrome phenotypes: a secondary analysis of randomised controlled trials. Lancet Respir Med. 2020;8(3):247–257. doi: 10.1016/s2213-2600(19)30369-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s2213-2600(19)30369-8</ArticleId><ArticleId IdType="pmc">PMC7543720</ArticleId><ArticleId IdType="pubmed">31948926</ArticleId></ArticleIdList></Reference><Reference><Citation>Bihari S., Bersten A., Paul E., McGuinness S., Dixon D., Sinha P., et al. Acute respiratory distress syndrome phenotypes with distinct clinical outcomes in PHARLAP trial cohort. Crit Care Resusc. 2021;23(2):163–170. doi: 10.51893/2021.2.oa3.</Citation><ArticleIdList><ArticleId IdType="doi">10.51893/2021.2.oa3</ArticleId><ArticleId IdType="pmc">PMC10692525</ArticleId><ArticleId IdType="pubmed">38045528</ArticleId></ArticleIdList></Reference><Reference><Citation>Battaglini D., Al-Husinat L., Normando A.G., Leme A.P., Franchini K., Morales M., et al. Personalized medicine using omics approaches in acute respiratory distress syndrome to identify biological phenotypes. Respir Res. 2022;23(1):318. doi: 10.1186/s12931-022-02233-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12931-022-02233-0</ArticleId><ArticleId IdType="pmc">PMC9675217</ArticleId><ArticleId IdType="pubmed">36403043</ArticleId></ArticleIdList></Reference><Reference><Citation>Bastarache J.A., McNeil J.B., Plosa E.J., Sucre J.S., Kerchberger V.E., Habegger L.E., et al. Standardization of methods for sampling the distal airspace in mechanically ventilated patients using heat moisture exchange filter fluid. Am J Physiol Lung Cell Mol Physiol. 2021;320(5):L785–L790. doi: 10.1152/ajplung.00595.2020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/ajplung.00595.2020</ArticleId><ArticleId IdType="pmc">PMC8174823</ArticleId><ArticleId IdType="pubmed">33655765</ArticleId></ArticleIdList></Reference><Reference><Citation>Metwaly S., Côté A., Donnelly S.J., Banoei M.M., Lee C.H., Andonegui G., et al. ARDS metabolic fingerprints: characterization, benchmarking, and potential mechanistic interpretation. Am J Physiol Lung Cell Mol Physiol. 2021;321(1):L79–L90. doi: 10.1152/ajplung.00077.2021.</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/ajplung.00077.2021</ArticleId><ArticleId IdType="pubmed">33949201</ArticleId></ArticleIdList></Reference><Reference><Citation>Martin T.R., Zemans R.L., Ware L.B., Schmidt E.P., Riches D.W.H., Bastarache L., et al. New insights into clinical and mechanistic heterogeneity of the acute respiratory distress syndrome: summary of the Aspen Lung Conference 2021. Am J Respir Cell Mol Biol. 2022;67(3):284–308. doi: 10.1165/rcmb.2022-0089WS.</Citation><ArticleIdList><ArticleId IdType="doi">10.1165/rcmb.2022-0089WS</ArticleId><ArticleId IdType="pmc">PMC9447141</ArticleId><ArticleId IdType="pubmed">35679511</ArticleId></ArticleIdList></Reference><Reference><Citation>Diray-Arce J., Fourati S., Doni Jayavelu N., Patel R., Maguire C., Chang A.C., et al. Multi-omic longitudinal study reveals immune correlates of clinical course among hospitalized COVID-19 patients. Cell Rep Med. 2023;4(6) doi: 10.1016/j.xcrm.2023.101079.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.xcrm.2023.101079</ArticleId><ArticleId IdType="pmc">PMC10203880</ArticleId><ArticleId IdType="pubmed">37327781</ArticleId></ArticleIdList></Reference><Reference><Citation>Neyton L.P.A., Langelier C.R., Calfee C.S. Metagenomic sequencing in the ICU for precision diagnosis of critical infectious illnesses. Crit Care. 2023;27(1):90. doi: 10.1186/s13054-023-04365-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13054-023-04365-1</ArticleId><ArticleId IdType="pmc">PMC10027598</ArticleId><ArticleId IdType="pubmed">36941644</ArticleId></ArticleIdList></Reference><Reference><Citation>Neyton L., Calfee C.S. Metabolic signatures of ARDS and ARDS heterogeneity. Am J Physiol Lung Cell Mol Physiol. 2021;321(6):L1067–L1068. doi: 10.1152/ajplung.00218.2021.</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/ajplung.00218.2021</ArticleId><ArticleId IdType="pmc">PMC8715022</ArticleId><ArticleId IdType="pubmed">34668417</ArticleId></ArticleIdList></Reference><Reference><Citation>Wick K.D., McAuley D.F., Levitt J.E., Beitler J.R., Annane D., Riviello E.D., et al. Promises and challenges of personalized medicine to guide ARDS therapy. Crit Care. 2021;25(1):404. doi: 10.1186/s13054-021-03822-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13054-021-03822-z</ArticleId><ArticleId IdType="pmc">PMC8609268</ArticleId><ArticleId IdType="pubmed">34814925</ArticleId></ArticleIdList></Reference><Reference><Citation>Hendrickson C.M., Calfee C.S. A new frontier in ARDS trials: phenotyping before randomisation. Lancet Respir Med. 2019;7(10):830–831. doi: 10.1016/s2213-2600(19)30175-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s2213-2600(19)30175-4</ArticleId><ArticleId IdType="pubmed">31399380</ArticleId></ArticleIdList></Reference><Reference><Citation>Shah F.A., Meyer N.J., Angus D.C., Awdish R., Azoulay É., Calfee C.S., et al. A research agenda for precision medicine in sepsis and acute respiratory distress syndrome: an Official American Thoracic Society Research Statement. Am J Respir Crit Care Med. 2021;204(8):891–901. doi: 10.1164/rccm.202108-1908ST.</Citation><ArticleIdList><ArticleId IdType="doi">10.1164/rccm.202108-1908ST</ArticleId><ArticleId IdType="pmc">PMC8534611</ArticleId><ArticleId IdType="pubmed">34652268</ArticleId></ArticleIdList></Reference><Reference><Citation>Reddy K., Calfee C.S., McAuley D.F. Acute respiratory distress syndrome subphenotypes beyond the syndrome: a step toward treatable traits? Am J Respir Crit Care Med. 2021;203(12):1449–1451. doi: 10.1164/rccm.202101-0218ED.</Citation><ArticleIdList><ArticleId IdType="doi">10.1164/rccm.202101-0218ED</ArticleId><ArticleId IdType="pmc">PMC8483225</ArticleId><ArticleId IdType="pubmed">33565943</ArticleId></ArticleIdList></Reference><Reference><Citation>Maslove D.M., Tang B., Shankar-Hari M., Lawler P.R., Angus D.C., Baillie J.K., et al. Redefining critical illness. Nat Med. 2022;28(6):1141–1148. doi: 10.1038/s41591-022-01843-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-022-01843-x</ArticleId><ArticleId IdType="pubmed">35715504</ArticleId></ArticleIdList></Reference><Reference><Citation>Sinha P., Kerchberger V.E., Willmore A., Chambers J., Zhuo H., Abbott J., et al. Identifying molecular phenotypes in sepsis: an analysis of two prospective observational cohorts and secondary analysis of two randomised controlled trials. Lancet Respir Med. 2023;11(11):965–974. doi: 10.1016/s2213-2600(23)00237-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s2213-2600(23)00237-0</ArticleId><ArticleId IdType="pmc">PMC10841178</ArticleId><ArticleId IdType="pubmed">37633303</ArticleId></ArticleIdList></Reference><Reference><Citation>Meduri G.U., Annane D., Confalonieri M., Chrousos G.P., Rochwerg B., Busby A., et al. Pharmacological principles guiding prolonged glucocorticoid treatment in ARDS. Intensive Care Med. 2020;46(12):2284–2296. doi: 10.1007/s00134-020-06289-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00134-020-06289-8</ArticleId><ArticleId IdType="pmc">PMC7641258</ArticleId><ArticleId IdType="pubmed">33150472</ArticleId></ArticleIdList></Reference><Reference><Citation>Wagner C., Griesel M., Mikolajewska A., Mueller A., Nothacker M., Kley K., et al. Systemic corticosteroids for the treatment of COVID-19. Cochrane Database Syst Rev. 2021;8(8) doi: 10.1002/14651858.Cd014963. Cd014963.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/14651858.Cd014963</ArticleId><ArticleId IdType="pmc">PMC8406706</ArticleId><ArticleId IdType="pubmed">34396514</ArticleId></ArticleIdList></Reference><Reference><Citation>Meduri G., Golden E., Freire A.X., Taylor E., Zaman M., Carson S.J., et al. Methylprednisolone infusion in early severe ARDS: results of a randomized controlled trial. Chest. 2007;131(4):954–963. doi: 10.1378/chest.06-2100.</Citation><ArticleIdList><ArticleId IdType="doi">10.1378/chest.06-2100</ArticleId><ArticleId IdType="pubmed">17426195</ArticleId></ArticleIdList></Reference><Reference><Citation>Steinberg K.P., Hudson L.D., Goodman R.B., Hough C.L., Lanken P.N., Hyzy R., et al. Efficacy and safety of corticosteroids for persistent acute respiratory distress syndrome. N Engl J Med. 2006;354(16):1671–1684. doi: 10.1056/NEJMoa051693.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa051693</ArticleId><ArticleId IdType="pubmed">16625008</ArticleId></ArticleIdList></Reference><Reference><Citation>Confalonieri M., Urbino R., Potena A., Piattella M., Parigi P., Puccio G., et al. Hydrocortisone infusion for severe community-acquired pneumonia: a preliminary randomized study. Am J Respir Crit Care Med. 2005;171(3):242–248. doi: 10.1164/rccm.200406-808OC.</Citation><ArticleIdList><ArticleId IdType="doi">10.1164/rccm.200406-808OC</ArticleId><ArticleId IdType="pubmed">15557131</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruan S., Lin H., Huang C., Kuo P.H., Wu H.D., Yu C.J. Exploring the heterogeneity of effects of corticosteroids on acute respiratory distress syndrome: a systematic review and meta-analysis. Crit Care. 2014;18(2):R63. doi: 10.1186/cc13819.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/cc13819</ArticleId><ArticleId IdType="pmc">PMC4056095</ArticleId><ArticleId IdType="pubmed">24708846</ArticleId></ArticleIdList></Reference><Reference><Citation>Brun-Buisson C., Richard J., Mercat A., Thiébaut A.C., Brochard L., REVA-SRLF A/H1N1v 2009 Registry Group Early corticosteroids in severe influenza A/H1N1 pneumonia and acute respiratory distress syndrome. Am J Respir Crit Care Med. 2011;183(9):1200–1206. doi: 10.1164/rccm.201101-0135OC.</Citation><ArticleIdList><ArticleId IdType="doi">10.1164/rccm.201101-0135OC</ArticleId><ArticleId IdType="pubmed">21471082</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu J., Zhang S., Dong X., Li Z., Xu Q., Feng H., et al. Corticosteroid treatment in severe COVID-19 patients with acute respiratory distress syndrome. J Clin Invest. 2020;130(12):6417–6428. doi: 10.1172/jci140617.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/jci140617</ArticleId><ArticleId IdType="pmc">PMC7685724</ArticleId><ArticleId IdType="pubmed">33141117</ArticleId></ArticleIdList></Reference><Reference><Citation>Arabi Y.M., Mandourah Y., Al-Hameed F., Sindi A.A., Almekhlafi G.A., Hussein M.A., et al. Corticosteroid therapy for critically ill patients with middle east respiratory syndrome. Am J Respir Crit Care Med. 2018;197(6):757–767. doi: 10.1164/rccm.201706-1172OC.</Citation><ArticleIdList><ArticleId IdType="doi">10.1164/rccm.201706-1172OC</ArticleId><ArticleId IdType="pubmed">29161116</ArticleId></ArticleIdList></Reference><Reference><Citation>Bone R.C., Fisher C.J., Jr., Clemmer T.P., Slotman G.J., Metz C.A. Early methylprednisolone treatment for septic syndrome and the adult respiratory distress syndrome. Chest. 1987;92(6):1032–1036. doi: 10.1378/chest.92.6.1032.</Citation><ArticleIdList><ArticleId IdType="doi">10.1378/chest.92.6.1032</ArticleId><ArticleId IdType="pubmed">3315478</ArticleId></ArticleIdList></Reference><Reference><Citation>Peter J.V., John P., Graham P.L., Moran J.L., George I.A., Bersten A. Corticosteroids in the prevention and treatment of acute respiratory distress syndrome (ARDS) in adults: meta-analysis. BMJ. 2008;336(7651):1006–1009. doi: 10.1136/bmj.39537.939039.BE.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.39537.939039.BE</ArticleId><ArticleId IdType="pmc">PMC2364864</ArticleId><ArticleId IdType="pubmed">18434379</ArticleId></ArticleIdList></Reference><Reference><Citation>Tongyoo S., Permpikul C., Mongkolpun W., Vattanavanit V., Udompanturak S., Kocak M., et al. Hydrocortisone treatment in early sepsis-associated acute respiratory distress syndrome: results of a randomized controlled trial. Crit Care. 2016;20(1):329. doi: 10.1186/s13054-016-1511-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13054-016-1511-2</ArticleId><ArticleId IdType="pmc">PMC5065699</ArticleId><ArticleId IdType="pubmed">27741949</ArticleId></ArticleIdList></Reference><Reference><Citation>Lewis S.R., Pritchard M.W., Thomas C.M., Smith A.F. Pharmacological agents for adults with acute respiratory distress syndrome. Cochrane Database Syst Rev. 2019;7(7) doi: 10.1002/14651858.CD004477.pub3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/14651858.CD004477.pub3</ArticleId><ArticleId IdType="pmc">PMC6646953</ArticleId><ArticleId IdType="pubmed">31334568</ArticleId></ArticleIdList></Reference><Reference><Citation>Meduri G.U., Bridges L., Shih M.C., Marik P.E., Siemieniuk R.A.C., Kocak M. Prolonged glucocorticoid treatment is associated with improved ARDS outcomes: analysis of individual patients' data from four randomized trials and trial-level meta-analysis of the updated literature. Intensive Care Med. 2016;42(5):829–840. doi: 10.1007/s00134-015-4095-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00134-015-4095-4</ArticleId><ArticleId IdType="pubmed">26508525</ArticleId></ArticleIdList></Reference><Reference><Citation>Villar J., Ferrando C., Martínez D., Ambrós A., Muñoz T., Soler J.A., et al. Dexamethasone treatment for the acute respiratory distress syndrome: a multicentre, randomised controlled trial. Lancet Respir Med. 2020;8(3):267–276. doi: 10.1016/s2213-2600(19)30417-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s2213-2600(19)30417-5</ArticleId><ArticleId IdType="pubmed">32043986</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang J.W., Jiang P., Wang W.W., Wen Z.M., Mao B., Lu H.W., et al. The controversy about the effects of different doses of corticosteroid treatment on clinical outcomes for acute respiratory distress syndrome patients: an observational study. Front Pharmacol. 2021;12 doi: 10.3389/fphar.2021.722537.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphar.2021.722537</ArticleId><ArticleId IdType="pmc">PMC8358143</ArticleId><ArticleId IdType="pubmed">34393800</ArticleId></ArticleIdList></Reference><Reference><Citation>Tasaka S., Ohshimo S., Takeuchi M., Yasuda H., Ichikado K., Tsushima K., et al. ARDS clinical practice guideline 2021. J Intensive Care. 2022;10(1):32. doi: 10.1186/s40560-022-00615-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40560-022-00615-6</ArticleId><ArticleId IdType="pmc">PMC9263056</ArticleId><ArticleId IdType="pubmed">35799288</ArticleId></ArticleIdList></Reference><Reference><Citation>Veterans Administration Systemic Sepsis Cooperative Study Group Effect of high-dose glucocorticoid therapy on mortality in patients with clinical signs of systemic sepsis. N Engl J Med. 1987;317(11):659–665. doi: 10.1056/nejm198709103171102.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/nejm198709103171102</ArticleId><ArticleId IdType="pubmed">2888017</ArticleId></ArticleIdList></Reference><Reference><Citation>Meduri G.U., Headley A.S., Golden E., Carson S.J., Umberger R.A., Kelso T., et al. Effect of prolonged methylprednisolone therapy in unresolving acute respiratory distress syndrome: a randomized controlled trial. JAMA. 1998;280(2):159–165. doi: 10.1001/jama.280.2.159.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.280.2.159</ArticleId><ArticleId IdType="pubmed">9669790</ArticleId></ArticleIdList></Reference><Reference><Citation>Balk R.A. Steroids for septic shock: back from the dead? (Pro) Chest. 2003;123(5 Suppl) doi: 10.1378/chest.123.5_suppl.490s. 490s–9s.</Citation><ArticleIdList><ArticleId IdType="doi">10.1378/chest.123.5_suppl.490s</ArticleId><ArticleId IdType="pubmed">12740234</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang B.M., Craig J.C., Eslick G.D., Seppelt I., McLean A.S. Use of corticosteroids in acute lung injury and acute respiratory distress syndrome: a systematic review and meta-analysis. Crit Care Med. 2009;37(5):1594–1603. doi: 10.1097/CCM.0b013e31819fb507.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/CCM.0b013e31819fb507</ArticleId><ArticleId IdType="pubmed">19325471</ArticleId></ArticleIdList></Reference><Reference><Citation>Meduri G.U., Annane D., Chrousos G.P., Marik P.E., Sinclair S.E. Activation and regulation of systemic inflammation in ARDS: rationale for prolonged glucocorticoid therapy. Chest. 2009;136(6):1631–1643. doi: 10.1378/chest.08-2408.</Citation><ArticleIdList><ArticleId IdType="doi">10.1378/chest.08-2408</ArticleId><ArticleId IdType="pubmed">19801579</ArticleId></ArticleIdList></Reference><Reference><Citation>Moran J.L., Graham P.L., Rockliff S., Bersten A.D. Updating the evidence for the role of corticosteroids in severe sepsis and septic shock: a Bayesian meta-analytic perspective. Crit Care. 2010;14(4):R134. doi: 10.1186/cc9182.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/cc9182</ArticleId><ArticleId IdType="pmc">PMC2945102</ArticleId><ArticleId IdType="pubmed">20626892</ArticleId></ArticleIdList></Reference><Reference><Citation>Keh D., Boehnke T., Weber-Cartens S., Schulz C., Ahlers O., Bercker S., et al. Immunologic and hemodynamic effects of "low-dose" hydrocortisone in septic shock: a double-blind, randomized, placebo-controlled, crossover study. Am J Respir Crit Care Med. 2003;167(4):512–520. doi: 10.1164/rccm.200205-446OC.</Citation><ArticleIdList><ArticleId IdType="doi">10.1164/rccm.200205-446OC</ArticleId><ArticleId IdType="pubmed">12426230</ArticleId></ArticleIdList></Reference><Reference><Citation>Jantz M.A., Sahn S.A. Corticosteroids in acute respiratory failure. Am J Respir Crit Care Med. 1999;160(4):1079–1100. doi: 10.1164/ajrccm.160.4.9901075.</Citation><ArticleIdList><ArticleId IdType="doi">10.1164/ajrccm.160.4.9901075</ArticleId><ArticleId IdType="pubmed">10508792</ArticleId></ArticleIdList></Reference><Reference><Citation>Annane D., Pastores S.M., Rochwerg B., Arlt W., Balk R.A., Beishuizen A., et al. Guidelines for the diagnosis and management of critical illness-related corticosteroid insufficiency (CIRCI) in critically ill patients (Part I): society of critical care medicine (SCCM) and European Society of Intensive Care Medicine (ESICM) 2017. Intensive Care Med. 2017;43(12):1751–1763. doi: 10.1007/s00134-017-4919-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00134-017-4919-5</ArticleId><ArticleId IdType="pubmed">28940011</ArticleId></ArticleIdList></Reference><Reference><Citation>Meduri G., Bridges L., Siemieniuk R., Kocak M. An exploratory reanalysis of the randomized trial on efficacy of corticosteroids as rescue therapy for the late phase of acute respiratory distress syndrome. Crit Care Med. 2018;46(6):884–891. doi: 10.1097/ccm.0000000000003021.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/ccm.0000000000003021</ArticleId><ArticleId IdType="pubmed">29432350</ArticleId></ArticleIdList></Reference><Reference><Citation>Hensley M.K., Sjoding M.W., Prescott H.C. COUNTERPOINT: should corticosteroids be routine treatment in early ARDS? No Chest. 2021;159(1):29–33. doi: 10.1016/j.chest.2020.07.059.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chest.2020.07.059</ArticleId><ArticleId IdType="pubmed">33422201</ArticleId></ArticleIdList></Reference><Reference><Citation>COVID-ICU Group on behalf of the REVA Network and the COVID-ICU Investigators Clinical characteristics and day-90 outcomes of 4244 critically ill adults with COVID-19: a prospective cohort study. Intensive Care Med. 2021;47(1):60–73. doi: 10.1007/s00134-020-06294-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00134-020-06294-x</ArticleId><ArticleId IdType="pmc">PMC7674575</ArticleId><ArticleId IdType="pubmed">33211135</ArticleId></ArticleIdList></Reference><Reference><Citation>Grasselli G., Greco M., Zanella A., Albano G., Antonelli M., Bellani G., et al. Risk factors associated with mortality among patients with COVID-19 in intensive care units in Lombardy, Italy. JAMA Intern Med. 2020;180(10):1345–1355. doi: 10.1001/jamainternmed.2020.3539.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamainternmed.2020.3539</ArticleId><ArticleId IdType="pmc">PMC7364371</ArticleId><ArticleId IdType="pubmed">32667669</ArticleId></ArticleIdList></Reference><Reference><Citation>Lamers M.M., Haagmans B.L. SARS-CoV-2 pathogenesis. Nat Rev Microbiol. 2022;20(5):270–284. doi: 10.1038/s41579-022-00713-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41579-022-00713-0</ArticleId><ArticleId IdType="pubmed">35354968</ArticleId></ArticleIdList></Reference><Reference><Citation>Bain W., Yang H., Shah F.A., Suber T., Drohan C., Al-Yousif N., et al. COVID-19 versus Non-COVID-19 acute respiratory distress syndrome: comparison of demographics, physiologic parameters, inflammatory biomarkers, and clinical outcomes. Ann Am Thorac Soc. 2021;18(7):1202–1210. doi: 10.1513/AnnalsATS.202008-1026OC.</Citation><ArticleIdList><ArticleId IdType="doi">10.1513/AnnalsATS.202008-1026OC</ArticleId><ArticleId IdType="pmc">PMC8328355</ArticleId><ArticleId IdType="pubmed">33544045</ArticleId></ArticleIdList></Reference><Reference><Citation>Sjoding M.W., Admon A.J., Saha A.K., Kay S.G., Brown C.A., Co I., et al. Comparing clinical features and outcomes in mechanically ventilated patients with COVID-19 and acute respiratory distress syndrome. Ann Am Thorac Soc. 2021;18(11):1876–1885. doi: 10.1513/AnnalsATS.202008-1076OC.</Citation><ArticleIdList><ArticleId IdType="doi">10.1513/AnnalsATS.202008-1076OC</ArticleId><ArticleId IdType="pmc">PMC8641825</ArticleId><ArticleId IdType="pubmed">33577740</ArticleId></ArticleIdList></Reference><Reference><Citation>Sinha S., Rosin N.L., Arora R., Labit E., Jaffer A., Cao L., et al. Dexamethasone modulates immature neutrophils and interferon programming in severe COVID-19. Nat Med. 2022;28(1):201–211. doi: 10.1038/s41591-021-01576-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01576-3</ArticleId><ArticleId IdType="pmc">PMC8799469</ArticleId><ArticleId IdType="pubmed">34782790</ArticleId></ArticleIdList></Reference><Reference><Citation>Siska P.J., Decking S.M., Babl N., Matos C., Bruss C., Singer K., et al. Metabolic imbalance of T cells in COVID-19 is hallmarked by basigin and mitigated by dexamethasone. J Clin Invest. 2021;131(22) doi: 10.1172/jci148225.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/jci148225</ArticleId><ArticleId IdType="pmc">PMC8592546</ArticleId><ArticleId IdType="pubmed">34779418</ArticleId></ArticleIdList></Reference><Reference><Citation>Cour M., Simon M., Argaud L., Monneret G., Venet F. Effects of dexamethasone on immune dysfunction and ventilator-associated pneumonia in COVID-19 acute respiratory distress syndrome: an observational study. J Intensive Care. 2021;9(1):64. doi: 10.1186/s40560-021-00580-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40560-021-00580-6</ArticleId><ArticleId IdType="pmc">PMC8522132</ArticleId><ArticleId IdType="pubmed">34663481</ArticleId></ArticleIdList></Reference><Reference><Citation>RECOVERY Collaborative. Horby P., Lim W.S., Emberson J.R., Mafham M., Bell J.L., et al. Dexamethasone in hospitalized patients with COVID-19. N Engl J Med. 2021;384(8):693–704. doi: 10.1056/NEJMoa2021436.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2021436</ArticleId><ArticleId IdType="pmc">PMC7383595</ArticleId><ArticleId IdType="pubmed">32678530</ArticleId></ArticleIdList></Reference><Reference><Citation>Chaudhuri D., Sasaki K., Karkar A., Sharif S., Lewis K., Mammen M.J., et al. Corticosteroids in COVID-19 and non-COVID-19 ARDS: a systematic review and meta-analysis. Intensive Care Med. 2021;47(5):521–537. doi: 10.1007/s00134-021-06394-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00134-021-06394-2</ArticleId><ArticleId IdType="pmc">PMC8054852</ArticleId><ArticleId IdType="pubmed">33876268</ArticleId></ArticleIdList></Reference><Reference><Citation>Mourad A., Thibault D., Holland T.L., Yang S., Young A.R., Arnold Egloff S.A., et al. Dexamethasone for inpatients with COVID-19 in a national cohort. JAMA Netw Open. 2023;6(4) doi: 10.1001/jamanetworkopen.2023.8516.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2023.8516</ArticleId><ArticleId IdType="pmc">PMC10111178</ArticleId><ArticleId IdType="pubmed">37067800</ArticleId></ArticleIdList></Reference><Reference><Citation>RECOVERY Collaborative Group Higher dose corticosteroids in patients admitted to hospital with COVID-19 who are hypoxic but not requiring ventilatory support (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet. 2023;401(10387):1499–1507. doi: 10.1016/s0140-6736(23)00510-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0140-6736(23)00510-x</ArticleId><ArticleId IdType="pmc">PMC10156147</ArticleId><ArticleId IdType="pubmed">37060915</ArticleId></ArticleIdList></Reference><Reference><Citation>Tomazini B.M., Maia I.S., Cavalcanti A.B., Berwanger O., Rosa R.G., Veiga V.C., et al. Effect of dexamethasone on days alive and ventilator-free in patients with moderate or severe acute respiratory distress syndrome and COVID-19: the CoDEX randomized clinical trial. JAMA. 2020;324(13):1307–1316. doi: 10.1001/jama.2020.17021.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2020.17021</ArticleId><ArticleId IdType="pmc">PMC7489411</ArticleId><ArticleId IdType="pubmed">32876695</ArticleId></ArticleIdList></Reference><Reference><Citation>Moreno G., Carbonell R., Martin-Loeches I., Solé-Violán J., Correig I Fraga E., Gómez J., et al. Corticosteroid treatment and mortality in mechanically ventilated COVID-19-associated acute respiratory distress syndrome (ARDS) patients: a multicentre cohort study. Ann Intensive Care. 2021;11(1):159. doi: 10.1186/s13613-021-00951-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13613-021-00951-0</ArticleId><ArticleId IdType="pmc">PMC8617372</ArticleId><ArticleId IdType="pubmed">34825976</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopinto J., Arrestier R., Peiffer B., Gaillet A., Voiriot G., Urbina T., et al. High-dose steroids for nonresolving acute respiratory distress syndrome in critically ill COVID-19 patients treated with dexamethasone: a multicenter cohort study. Crit Care Med. 2023;51(10):1306–1317. doi: 10.1097/ccm.0000000000005930.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/ccm.0000000000005930</ArticleId><ArticleId IdType="pubmed">37199534</ArticleId></ArticleIdList></Reference><Reference><Citation>Torres A., Motos A., Cillóniz C., Ceccato A., Fernández-Barat L., Gabarrús A., et al. Major candidate variables to guide personalised treatment with steroids in critically ill patients with COVID-19: CIBERESUCICOVID study. Intensive Care Med. 2022;48(7):850–864. doi: 10.1007/s00134-022-06726-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00134-022-06726-w</ArticleId><ArticleId IdType="pmc">PMC9211796</ArticleId><ArticleId IdType="pubmed">35727348</ArticleId></ArticleIdList></Reference><Reference><Citation>Reyes L.F., Rodriguez A., Bastidas A., Parra-Tanoux D., Fuentes Y.V., García-Gallo E., et al. Dexamethasone as risk-factor for ICU-acquired respiratory tract infections in severe COVID-19. J Critical Care. 2022;69 doi: 10.1016/j.jcrc.2022.154014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jcrc.2022.154014</ArticleId><ArticleId IdType="pmc">PMC8863516</ArticleId><ArticleId IdType="pubmed">35217370</ArticleId></ArticleIdList></Reference><Reference><Citation>Lamouche-Wilquin P., Souchard J., Pere M., Raymond M., Asfar P., Darreau C., et al. Early steroids and ventilator-associated pneumonia in COVID-19-related ARDS. Crit Care. 2022;26(1):233. doi: 10.1186/s13054-022-04097-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13054-022-04097-8</ArticleId><ArticleId IdType="pmc">PMC9344449</ArticleId><ArticleId IdType="pubmed">35918776</ArticleId></ArticleIdList></Reference><Reference><Citation>Gragueb-Chatti I., Lopez A., Hamidi D., Guervilly C., Loundou A., Daviet F., et al. Impact of dexamethasone on the incidence of ventilator-associated pneumonia and blood stream infections in COVID-19 patients requiring invasive mechanical ventilation: a multicenter retrospective study. Ann Intensive Care. 2021;11(1):87. doi: 10.1186/s13613-021-00876-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13613-021-00876-8</ArticleId><ArticleId IdType="pmc">PMC8165680</ArticleId><ArticleId IdType="pubmed">34057642</ArticleId></ArticleIdList></Reference><Reference><Citation>Chalmers J.D., Crichton M.L., Goeminne P.C., Cao B., Humbert M., Shteinberg M., et al. Management of hospitalised adults with coronavirus disease 2019 (COVID-19): a European Respiratory Society living guideline. Eur Respir J. 2021;57(4) doi: 10.1183/13993003.00048-2021.</Citation><ArticleIdList><ArticleId IdType="doi">10.1183/13993003.00048-2021</ArticleId><ArticleId IdType="pmc">PMC7947358</ArticleId><ArticleId IdType="pubmed">33692120</ArticleId></ArticleIdList></Reference><Reference><Citation>Venkatesh B., Finfer S., Cohen J., Rajbhandari D., Arabi Y., Bellomo R., et al. Adjunctive glucocorticoid therapy in patients with septic shock. N Engl J Med. 2018;378(9):797–808. doi: 10.1056/NEJMoa1705835.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1705835</ArticleId><ArticleId IdType="pubmed">29347874</ArticleId></ArticleIdList></Reference><Reference><Citation>Annane D., Renault A., Brun-Buisson C., Megarbane B., Quenot J.P., Siami S., et al. Hydrocortisone plus fludrocortisone for adults with septic shock. N Engl J Med. 2018;378(9):809–818. doi: 10.1056/NEJMoa1705716.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1705716</ArticleId><ArticleId IdType="pubmed">29490185</ArticleId></ArticleIdList></Reference><Reference><Citation>Martinez-Guerra B.A., Gonzalez-Lara M.F., Roman-Montes C.M., Tamez-Torres K.M., Dardón-Fierro F.E., Rajme-Lopez S., et al. Outcomes of patients with severe and critical COVID-19 treated with dexamethasone: a prospective cohort study. Emerg Microbes Infect. 2022;11(1):50–59. doi: 10.1080/22221751.2021.2011619.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/22221751.2021.2011619</ArticleId><ArticleId IdType="pmc">PMC8725849</ArticleId><ArticleId IdType="pubmed">34839785</ArticleId></ArticleIdList></Reference><Reference><Citation>Fang F., Zhang Y., Tang J., Lunsford L.D., Li T., Tang R., et al. Association of corticosteroid treatment with outcomes in adult patients with sepsis: a systematic review and meta-analysis. JAMA Intern Med. 2019;179(2):213–223. doi: 10.1001/jamainternmed.2018.5849.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamainternmed.2018.5849</ArticleId><ArticleId IdType="pmc">PMC6439648</ArticleId><ArticleId IdType="pubmed">30575845</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang X., Li S., Fu Y., Dang H., Liu C. Safety and efficacy of corticosteroids in ARDS patients: a systematic review and meta-analysis of RCT data. Respir Res. 2022;23(1):301. doi: 10.1186/s12931-022-02186-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12931-022-02186-4</ArticleId><ArticleId IdType="pmc">PMC9635104</ArticleId><ArticleId IdType="pubmed">36333729</ArticleId></ArticleIdList></Reference><Reference><Citation>Rygård S.L., Butler E., Granholm A., Møller M.H., Cohen J., Finfer S., et al. Low-dose corticosteroids for adult patients with septic shock: a systematic review with meta-analysis and trial sequential analysis. Intensive Care Med. 2018;44(7):1003–1016. doi: 10.1007/s00134-018-5197-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00134-018-5197-6</ArticleId><ArticleId IdType="pubmed">29761216</ArticleId></ArticleIdList></Reference><Reference><Citation>Torres A., Sibila O., Ferrer M., Polverino E., Menendez R., Mensa J., et al. Effect of corticosteroids on treatment failure among hospitalized patients with severe community-acquired pneumonia and high inflammatory response: a randomized clinical trial. JAMA. 2015;313(7):677–686. doi: 10.1001/jama.2015.88.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2015.88</ArticleId><ArticleId IdType="pubmed">25688779</ArticleId></ArticleIdList></Reference><Reference><Citation>Sardu C., D'Onofrio N., Balestrieri M.L., Barbieri M., Rizzo M.R., Messina V., et al. Outcomes in patients with hyperglycemia affected by COVID-19: can we do more on glycemic control? Diabetes Care. 2020;43(7):1408–1415. doi: 10.2337/dc20-0723.</Citation><ArticleIdList><ArticleId IdType="doi">10.2337/dc20-0723</ArticleId><ArticleId IdType="pmc">PMC7305003</ArticleId><ArticleId IdType="pubmed">32430456</ArticleId></ArticleIdList></Reference><Reference><Citation>Alhazzani W., Alshahrani M., Jaeschke R., Forel J.M., Papazian L., Sevransky J., et al. Neuromuscular blocking agents in acute respiratory distress syndrome: a systematic review and meta-analysis of randomized controlled trials. Crit Care. 2013;17(2):R43. doi: 10.1186/cc12557.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/cc12557</ArticleId><ArticleId IdType="pmc">PMC3672502</ArticleId><ArticleId IdType="pubmed">23497608</ArticleId></ArticleIdList></Reference><Reference><Citation>National Heart, Lung, and Blood Institute PETAL Clinical Trials Network. Moss M., Huang D.T., Brower R.G., Ferguson N.D., Ginde A.A., et al. Early neuromuscular blockade in the acute respiratory distress syndrome. N Engl J Med. 2019;380(21):1997–2008. doi: 10.1056/NEJMoa1901686.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1901686</ArticleId><ArticleId IdType="pmc">PMC6741345</ArticleId><ArticleId IdType="pubmed">31112383</ArticleId></ArticleIdList></Reference><Reference><Citation>Behbehani N.A., Al-Mane F., D'yachkova Y., Paré P., FitzGerald J.M. Myopathy following mechanical ventilation for acute severe asthma: the role of muscle relaxants and corticosteroids. Chest. 1999;115(6):1627–1631. doi: 10.1378/chest.115.6.1627.</Citation><ArticleIdList><ArticleId IdType="doi">10.1378/chest.115.6.1627</ArticleId><ArticleId IdType="pubmed">10378560</ArticleId></ArticleIdList></Reference><Reference><Citation>Stevens R.D., Dowdy D.W., Michaels R.K., Mendez-Tellez P.A., Pronovost P.J., Needham D.M. Neuromuscular dysfunction acquired in critical illness: a systematic review. Intensive Care Med. 2007;33(11):1876–1891. doi: 10.1007/s00134-007-0772-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00134-007-0772-2</ArticleId><ArticleId IdType="pubmed">17639340</ArticleId></ArticleIdList></Reference><Reference><Citation>Hermans G., Wilmer A., Meersseman W., Milants I., Wouters P.J., Bobbaers H., et al. Impact of intensive insulin therapy on neuromuscular complications and ventilator dependency in the medical intensive care unit. Am J Respir Crit Care Med. 2007;175(5):480–489. doi: 10.1164/rccm.200605-665OC.</Citation><ArticleIdList><ArticleId IdType="doi">10.1164/rccm.200605-665OC</ArticleId><ArticleId IdType="pubmed">17138955</ArticleId></ArticleIdList></Reference><Reference><Citation>Dendoncker K., Libert C. Glucocorticoid resistance as a major drive in sepsis pathology. Cytokine Growth Factor Rev. 2017;35:85–96. doi: 10.1016/j.cytogfr.2017.04.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cytogfr.2017.04.002</ArticleId><ArticleId IdType="pubmed">28479044</ArticleId></ArticleIdList></Reference><Reference><Citation>Nicolaides N.C., Charmandari E. Novel insights into the molecular mechanisms underlying generalized glucocorticoid resistance and hypersensitivity syndromes. Hormones. 2017;16(2):124–138. doi: 10.14310/horm.2002.1728.</Citation><ArticleIdList><ArticleId IdType="doi">10.14310/horm.2002.1728</ArticleId><ArticleId IdType="pubmed">28742501</ArticleId></ArticleIdList></Reference><Reference><Citation>Annane D., Pastores S.M., Arlt W., Balk R.A., Beishuizen A., Briegel J., et al. Critical illness-related corticosteroid insufficiency (CIRCI): a narrative review from a multispecialty task force of the society of critical care medicine (SCCM) and the European Society of Intensive Care Medicine (ESICM) Crit Care Med. 2017;45(12):2089–2098. doi: 10.1097/ccm.0000000000002724.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/ccm.0000000000002724</ArticleId><ArticleId IdType="pubmed">28938251</ArticleId></ArticleIdList></Reference><Reference><Citation>Buttgereit F., Bijlsma J.W.J., Strehl C. Will we ever have better glucocorticoids? Clin Immunol. 2018;186:64–66. doi: 10.1016/j.clim.2017.07.023.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clim.2017.07.023</ArticleId><ArticleId IdType="pubmed">28757452</ArticleId></ArticleIdList></Reference><Reference><Citation>Meduri G.U., Kanangat S. Glucocorticoid treatment of sepsis and acute respiratory distress syndrome: time for a critical reappraisal. Crit Care Med. 1998;26(4):630–633. doi: 10.1097/00003246-199804000-00003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00003246-199804000-00003</ArticleId><ArticleId IdType="pubmed">9559593</ArticleId></ArticleIdList></Reference><Reference><Citation>Dinsen S., Baslund B., Klose M., Rasmussen A.K., Friis-Hansen L., Hilsted L., et al. Why glucocorticoid withdrawal may sometimes be as dangerous as the treatment itself. Eur J Intern Med. 2013;24(8):714–720. doi: 10.1016/j.ejim.2013.05.014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejim.2013.05.014</ArticleId><ArticleId IdType="pubmed">23806261</ArticleId></ArticleIdList></Reference><Reference><Citation>Bernard G.R., Luce J.M., Sprung C.L., Rinaldo J.E., Tate R.M., Sibbald W.J., et al. High-dose corticosteroids in patients with the adult respiratory distress syndrome. N Engl J Med. 1987;317(25):1565–1570. doi: 10.1056/nejm198712173172504.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/nejm198712173172504</ArticleId><ArticleId IdType="pubmed">3317054</ArticleId></ArticleIdList></Reference><Reference><Citation>Annane D., Sébille V., Bellissant E. Effect of low doses of corticosteroids in septic shock patients with or without early acute respiratory distress syndrome. Crit Care Med. 2006;34(1):22–30. doi: 10.1097/01.ccm.0000194723.78632.62.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/01.ccm.0000194723.78632.62</ArticleId><ArticleId IdType="pubmed">16374152</ArticleId></ArticleIdList></Reference><Reference><Citation>Meijvis S.C., Hardeman H., Remmelts H.H., Heijligenberg R., Rijkers G.T., van Velzen-Blad H., et al. Dexamethasone and length of hospital stay in patients with community-acquired pneumonia: a randomised, double-blind, placebo-controlled trial. Lancet. 2011;377(9782):2023–2030. doi: 10.1016/s0140-6736(11)60607-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0140-6736(11)60607-7</ArticleId><ArticleId IdType="pubmed">21636122</ArticleId></ArticleIdList></Reference><Reference><Citation>Angus D.C., Derde L., Al-Beidh F., Annane D., Arabi Y., Beane A., et al. Effect of hydrocortisone on mortality and organ support in patients with severe COVID-19: the REMAP-CAP COVID-19 corticosteroid domain randomized clinical trial. JAMA. 2020;324(13):1317–1329. doi: 10.1001/jama.2020.17022.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2020.17022</ArticleId><ArticleId IdType="pmc">PMC7489418</ArticleId><ArticleId IdType="pubmed">32876697</ArticleId></ArticleIdList></Reference><Reference><Citation>Maskin L.P., Bonelli I., Olarte G.L., Palizas F., Jr., Velo A.E., Lurbet M.F., et al. High- versus low-dose dexamethasone for the treatment of COVID-19-related acute respiratory distress syndrome: a multicenter, randomized open-label clinical trial. J Intensive Care Med. 2022;37(4):491–499. doi: 10.1177/08850666211066799.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/08850666211066799</ArticleId><ArticleId IdType="pmc">PMC8926919</ArticleId><ArticleId IdType="pubmed">34898320</ArticleId></ArticleIdList></Reference><Reference><Citation>Scaravilli V., Guzzardella A., Madotto F., Beltrama V., Muscatello A., Bellani G., et al. Impact of dexamethasone on the incidence of ventilator-associated pneumonia in mechanically ventilated COVID-19 patients: a propensity-matched cohort study. Crit Care. 2022;26(1):176. doi: 10.1186/s13054-022-04049-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13054-022-04049-2</ArticleId><ArticleId IdType="pmc">PMC9191402</ArticleId><ArticleId IdType="pubmed">35698155</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>